SELECT trial: difference between revisions
Diff·revision 19 → 20·12:45, 10 Aug 2025
Difference between revision 19 and revision 20 of SELECT trial. 5 lines changed; the page grew by 320 bytes.
| Revision 19 — 15:26, 16 Jul 2025 PioneerPerdita (talk) alphabetise the see-also list 4,851 bytes ±0 | Revision 20 — 12:45, 10 Aug 2025 DataTableDunja (talk) rm the cross-trial comparison; the populations are not comparable 5,171 bytes +320 | ||
|---|---|---|---|
| 38 | It does not establish benefit in primary prevention, in people without overweight or obesity, or for other members of the [[GLP-1 receptor agonist|class]]. Within the class, the outcome trials have not all been positive — the exenatide trial was neutral and the lixisenatide trial was neutral — so a class claim is not supported. See [[Exenatide]].{{r|marso2016s}} | 38 | It does not establish benefit in primary prevention, in people without overweight or obesity, or for other members of the [[GLP-1 receptor agonist|class]]. Within the class, the outcome trials have not all been positive — the exenatide trial was neutral and the lixisenatide trial was neutral — so a class claim is not supported. See [[Exenatide]].{{r|marso2016s}} |
| 39 | 39 | ||
| + | 40 | The 16.6% discontinuation for adverse events against 8.2% on placebo is the other side of the result and belongs in any summary of it. See [[Adverse effects of GLP-1 receptor agonists]].{{r|lincoff2023}} | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |
| ⋮ | ⋮ | ||
| 44 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 46 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| 45 | <ref name="nnt_ref">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> | 47 | <ref name="nnt_ref">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> |
| + | 48 | ||
| + | 49 | == External links == | |
| + | 50 | * [https://clinicaltrials.gov/study/NCT03574597 SELECT — NCT03574597] — Registry record. | |
| 46 | 51 | ||
| 47 | == See also == | 52 | == See also == |